Department of Gynecology and Obstetrics, XinHua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai 200092, China.
DWI-Leibniz-Institute for Interactive Materials e.V., 52056 Aachen, Germany.
J Adv Res. 2021 Aug 11;37:255-266. doi: 10.1016/j.jare.2021.08.004. eCollection 2022 Mar.
The striking imbalance between the ever-increasing amount of nanomedicines and low clinical translation of products has become the focus of intense debate. For clinical translation, the critical issue is to select the appropriate agents and combination regimen for targeted diseases, not to prepare increasingly complex nanoplatforms.
A safe and efficient platform, α-tocopheryl succinate (α-TOS) married 2D molybdenum disulfide, was devised by a facile method and applied for cooperative imaging-guided photothermal-selective chemotherapy of ovarian carcinoma.
A novel platform of PEGylated α-TOS and folic acid (FA) conjugated 2D MoS nanoflakes was fabricated for the cooperative multimode computed tomography (CT)/photoacoustic (PA)/thermal imaging-guided photothermal-selective chemotherapy of ovarian carcinoma.
The photothermal efficiency (65.3%) of the platform under safe near-infrared irradiation is much higher than that of other photothermal materials reported elsewhere. Moreover, the covalently linked α-TOS renders platform with selective chemotherapy for cancer cells. Remarkably, with these excellent properties, the platform can be used to completely eliminate the solid tumor by safe photothermal therapy, and then kill the residual cancer cells by selective chemotherapy to prevent tumor recurrence. More significantly, barely side effects occur in the whole treatment process. The excellent efficacy and safety benefits lead to the prominent survival rate of 100% over 91 days.
The safe and efficient platform might be a candidate of clinical nanomedicines for multimode theranostics. This study demonstrates an innovative thought in precise nanomedicine regarding the design of next generation of cancer theranostic protocol for potential clinical practice.
不断增加的纳米药物数量与产品低临床转化率之间的巨大不平衡已成为激烈争论的焦点。对于临床转化而言，关键问题是针对目标疾病选择合适的药物和联合治疗方案，而不是制备日益复杂的纳米平台。
通过简便的方法设计了安全有效的平台，即α-生育酚琥珀酸酯（α-TOS）与二维二硫化钼结合，并将其应用于卵巢癌的协同成像引导光热-化疗。
通过简便的方法制备了聚乙二醇化α-TOS 和叶酸（FA）修饰的二维 MoS 纳米片的新型平台，用于协同多模式计算机断层扫描（CT）/光声（PA）/热成像引导的卵巢癌光热选择性化疗。
在安全的近红外辐射下，该平台的光热效率（65.3%）明显高于其他报道的光热材料。此外，共价连接的α-TOS 赋予平台对癌细胞的选择性化疗。值得注意的是，该平台具有这些优异的性能，可通过安全的光热疗法完全消除实体肿瘤，然后通过选择性化疗杀死残留的癌细胞，以防止肿瘤复发。更重要的是，整个治疗过程中几乎没有副作用。优异的疗效和安全性使 91 天的存活率达到 100%。
安全有效的平台可能成为临床纳米药物的候选者，用于多模式治疗。本研究为下一代癌症治疗协议的设计提供了一种创新的精准纳米医学思路，为潜在的临床实践提供了新的思路。
